Antitumor activity studies of newly synthesized N-salicyloyl-N'-(p-hydroxybenzthioyl)hydrazine and its copper(II) complex both in vivo and in vitro.
A new ligand N-salicyloyl-N'-(p-hydroxybenzthioyl) hydrazine (H2STPH) and its Cu(II) complex [Cu(SPTH)] were prepared and characterized by analytical and physicochemical studies. In vivo antitumor activity of [Cu(STPH)] has been tested against breast tumor in C3H/J strain mice and in vitro on P-815 (murine mastocytoma) and K-562 (human erythroleukemia) cells. LD50 values were estimated at a dose level of 100 mg/kg body weight and a light microscopic study also carried out.